{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T01:20:19Z","timestamp":1787966419958,"version":"build-2784847793"},"reference-count":98,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,27]],"date-time":"2024-06-27T00:00:00Z","timestamp":1719446400000},"content-version":"am","delay-in-days":362,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Reviews"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.blre.2023.101094","type":"journal-article","created":{"date-parts":[[2023,4,27]],"date-time":"2023-04-27T21:00:14Z","timestamp":1682629214000},"page":"101094","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Beyond current treatment of Fanconi Anemia: What do advances in cell and gene-based approaches offer?"],"prefix":"10.1016","volume":"60","author":[{"given":"Elena","family":"Mart\u00ednez-Balsalobre","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Hugues","family":"Guervilly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenny","family":"van Asbeck-van der Wijst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Bel\u00e9n","family":"P\u00e9rez-Oliva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Lachaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.blre.2023.101094_bb0005","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1016\/j.trecan.2017.10.005","article-title":"Fanconi anemia signaling and cancer","volume":"3","author":"Nepal","year":"2017","journal-title":"Trends Cancer"},{"key":"10.1016\/j.blre.2023.101094_bb0010","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/nrc.2017.116","article-title":"Fanconi anaemia and cancer: an intricate relationship","volume":"18","author":"Nalepa","year":"2018","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.blre.2023.101094_bb0015","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.jaad.2021.01.029","article-title":"Skin cancer and sun protection practices in Fanconi anemia patients: a cross-sectional study","volume":"86","author":"Ruggiero","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.blre.2023.101094_bb0020","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1210\/jc.2014-4357","article-title":"Endocrine disorders in Fanconi Anemia: recommendations for screening and treatment","volume":"100","author":"Petryk","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.blre.2023.101094_bb0025","article-title":"Endocrine profiling in patients with Fanconi anemia, homozygous for a FANCG founder mutation","volume":"8","author":"Dillon","year":"2020","journal-title":"Mol Genetics Genom Medicine"},{"key":"10.1016\/j.blre.2023.101094_bb0030","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.stem.2012.05.013","article-title":"Bone marrow failure in Fanconi Anemia is triggered by an exacerbated p53\/p21 DNA damage response that impairs hematopoietic stem and progenitor cells","volume":"11","author":"Ceccaldi","year":"2012","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.blre.2023.101094_bb0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2019.100589","article-title":"Genotype-phenotype associations in Fanconi anemia: a literature review","volume":"37","author":"Fiesco-Roa","year":"2019","journal-title":"Blood Rev"},{"key":"10.1016\/j.blre.2023.101094_bb0040","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1089\/hum.2018.124","article-title":"Advances in gene therapy for Fanconi Anemia","volume":"29","author":"R\u00edo","year":"2018","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.blre.2023.101094_bb0045","doi-asserted-by":"crossref","first-page":"2971","DOI":"10.1182\/blood-2016-01-583625","article-title":"How I treat MDS and AML in Fanconi anemia","volume":"127","author":"de Latour","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.blre.2023.101094_bb0050","doi-asserted-by":"crossref","first-page":"30","DOI":"10.3324\/haematol.2017.178111","article-title":"Cancer in the National Cancer Institute inherited bone marrow failure syndrome cohort after fifteen years of follow-up","volume":"103","author":"Alter","year":"2018","journal-title":"Haematologica"},{"key":"10.1016\/j.blre.2023.101094_bb0055","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1038\/nature11368","article-title":"Genotoxic consequences of endogenous aldehydes on mouse haematopoietic stem cell function","volume":"489","author":"Garaycoechea","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.blre.2023.101094_bb0060","doi-asserted-by":"crossref","first-page":"3097","DOI":"10.1007\/s00018-016-2218-x","article-title":"Cellular response to DNA interstrand crosslinks: the Fanconi anemia pathway","volume":"73","author":"Lopez-Martinez","year":"2016","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.blre.2023.101094_bb0065","doi-asserted-by":"crossref","first-page":"6275","DOI":"10.3390\/ijms22126275","article-title":"Cell and gene therapy for Anemia: hematopoietic stem cells and gene editing","volume":"22","author":"Anurogo","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.blre.2023.101094_bb0070","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1182\/asheducation-2011.1.492","article-title":"Fanconi Anemia","volume":"2011","author":"Soulier","year":"2011","journal-title":"Hematology"},{"key":"10.1016\/j.blre.2023.101094_bb0075","series-title":"GeneReviews\u00ae [Internet]","article-title":"Fanconi Anemia. 2002 Feb 14 [Updated 2021 Jun 3]","author":"Mehta","year":"1993"},{"key":"10.1016\/j.blre.2023.101094_bb0080","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/j.celrep.2014.04.029","article-title":"Modularized functions of the Fanconi Anemia Core complex","volume":"7","author":"Huang","year":"2014","journal-title":"Cell Rep"},{"key":"10.1016\/j.blre.2023.101094_bb0085","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S1097-2765(01)00173-3","article-title":"Interaction of the Fanconi Anemia proteins and BRCA1 in a common pathway","volume":"7","author":"Garcia-Higuera","year":"2001","journal-title":"Mol Cell"},{"key":"10.1016\/j.blre.2023.101094_bb0090","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.molcel.2014.03.015","article-title":"XPF-ERCC1 acts in unhooking DNA interstrand crosslinks in cooperation with FANCD2 and FANCP\/SLX4","volume":"54","author":"Klein Douwel","year":"2014","journal-title":"Mol Cell"},{"key":"10.1016\/j.blre.2023.101094_bb0095","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1146\/annurev-biochem-080320-112510","article-title":"Mechanisms of vertebrate DNA interstrand cross-link repair","volume":"90","author":"Semlow","year":"2021","journal-title":"Annu Rev Biochem"},{"key":"10.1016\/j.blre.2023.101094_bb0100","doi-asserted-by":"crossref","first-page":"585","DOI":"10.3390\/genes11050585","article-title":"The FANC\/BRCA pathway releases replication blockades by eliminating DNA Interstrand cross-links","volume":"11","author":"Renaudin","year":"2020","journal-title":"Genes-Basel"},{"key":"10.1016\/j.blre.2023.101094_bb0105","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.mrfmmm.2017.09.004","article-title":"Beyond interstrand crosslinks repair: contribution of FANCD2 and other Fanconi Anemia proteins to the replication of DNA","volume":"808","author":"Federico","year":"2018","journal-title":"Mutat Res Fundam Mol Mech Mutagen"},{"key":"10.1016\/j.blre.2023.101094_bb0110","doi-asserted-by":"crossref","first-page":"4007","DOI":"10.1083\/jcb.201702136","article-title":"Fanconi anemia FANCD2 and FANCI proteins regulate the nuclear dynamics of splicing factors","volume":"216","author":"Moriel-Carretero","year":"2017","journal-title":"J Cell Biol"},{"key":"10.1016\/j.blre.2023.101094_bb0115","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1073\/pnas.1811557116","article-title":"Fanconi anemia protein FANCI functions in ribosome biogenesis","volume":"116","author":"Sondalle","year":"2019","journal-title":"Proc National Acad Sci"},{"key":"10.1016\/j.blre.2023.101094_bb0120","doi-asserted-by":"crossref","first-page":"eabb5414","DOI":"10.1126\/sciadv.abb5414","article-title":"Fanconi anemia a protein participates in nucleolar homeostasis maintenance and ribosome biogenesis","volume":"7","author":"Gueiderikh","year":"2021","journal-title":"Sci Adv"},{"key":"10.1016\/j.blre.2023.101094_bb0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2021.100904","article-title":"A new frontier in Fanconi anemia: from DNA repair to ribosome biogenesis","volume":"52","author":"Gueiderikh","year":"2022","journal-title":"Blood Rev"},{"key":"10.1016\/j.blre.2023.101094_bb0130","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.3390\/cancers12092684","article-title":"Canonical and noncanonical roles of Fanconi Anemia proteins: implications in cancer predisposition","volume":"12","author":"Milletti","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.blre.2023.101094_bb0135","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1038\/bmt.2016.32","article-title":"Late effects in patients with Fanconi anemia following allogeneic hematopoietic stem cell transplantation from alternative donors","volume":"51","author":"Anur","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.blre.2023.101094_bb0140","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1182\/blood-2004-04-1652","article-title":"Risk of head and neck squamous cell cancer and death in patients with Fanconi anemia who did and did not receive transplants","volume":"105","author":"Rosenberg","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.blre.2023.101094_bb0145","doi-asserted-by":"crossref","first-page":"4279","DOI":"10.1182\/blood-2013-01-479733","article-title":"Allogeneic hematopoietic stem cell transplantation in Fanconi anemia: the European Group for Blood and Marrow Transplantation experience","volume":"122","author":"de Latour","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.blre.2023.101094_bb0150","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1182\/blood-2018-99-111764","article-title":"Incidence of acute graft-versus-host disease and survival after allogeneic hematopoietic cell transplantation over time: a study from the transplant complications and chronic malignancies working party of the EBMT","volume":"132","author":"Greinix","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.blre.2023.101094_bb0155","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.bbmt.2014.10.021","article-title":"Increasing incidence of chronic graft-versus-host disease in allogeneic transplantation: a report from the Center for International Blood and Marrow Transplant Research","volume":"21","author":"Arai","year":"2015","journal-title":"Biol Blood Marrow Tr"},{"key":"10.1016\/j.blre.2023.101094_bb0160","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1038\/bmt.2013.204","volume":"49","author":"Baron","year":"2014","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.blre.2023.101094_bb0165","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1182\/bloodadvances.2020002444","article-title":"\u03b1\u03b2 T-cell graft depletion for allogeneic HSCT in adults with hematological malignancies","volume":"5","author":"de Witte","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.blre.2023.101094_bb0170","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.bbmt.2016.12.633","volume":"23","author":"Barba","year":"2017","journal-title":"Biol Blood Marrow Tr"},{"key":"10.1016\/j.blre.2023.101094_bb0175","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1186\/s13045-018-0668-3","article-title":"Ex vivo and in vivo T cell-depleted allogeneic stem cell transplantation in patients with acute myeloid leukemia in first complete remission resulted in similar overall survival: on behalf of the ALWP of the EBMT and the MSKCC","volume":"11","author":"Malard","year":"2018","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.blre.2023.101094_bb0180","doi-asserted-by":"crossref","first-page":"e228","DOI":"10.1016\/S2352-3026(22)00032-1","article-title":"Transplantation for Fanconi anaemia: lessons learned from Brazil","volume":"9","author":"Bonfim","year":"2022","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.blre.2023.101094_bb0185","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/j.bbmt.2017.11.031","article-title":"Comparable outcomes after HLA-matched sibling and alternative donor hematopoietic cell transplantation for children with Fanconi Anemia and severe aplastic Anemia","volume":"24","author":"Ebens","year":"2018","journal-title":"Biol Blood Marrow Tr"},{"key":"10.1016\/j.blre.2023.101094_bb0190","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1182\/bloodadvances.2020003707","article-title":"HLA-haploidentical TCR\u03b1\u03b2+\/CD19+-depleted stem cell transplantation in children and young adults with Fanconi anemia","volume":"5","author":"Strocchio","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.blre.2023.101094_bb0195","doi-asserted-by":"crossref","first-page":"3798","DOI":"10.1182\/blood-2015-02-626002","article-title":"Alternative donor hematopoietic cell transplantation for Fanconi anemia","volume":"125","author":"MacMillan","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.blre.2023.101094_bb0200","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1111\/bjh.17418","article-title":"Excellent overall and chronic graft-versus-host-disease-free event-free survival in Fanconi anaemia patients undergoing matched related- and unrelated-donor bone marrow transplantation using alemtuzumab\u2013Flu\u2013Cy: the UK experience","volume":"193","author":"Bernard","year":"2021","journal-title":"Brit J Haematol"},{"key":"10.1016\/j.blre.2023.101094_bb0205","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1002\/ajh.25810","article-title":"Outcome of patients with Fanconi anemia developing myelodysplasia and acute leukemia who received allogeneic hematopoietic stem cell transplantation: a retrospective analysis on behalf of EBMT group","volume":"95","author":"Giardino","year":"2020","journal-title":"Am J Hematol"},{"key":"10.1016\/j.blre.2023.101094_bb0210","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1056\/NEJMoa1410863","article-title":"Chimpanzee adenovirus vector Ebola vaccine","volume":"376","author":"Ledgerwood","year":"2017","journal-title":"New Engl J Med"},{"key":"10.1016\/j.blre.2023.101094_bb0215","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/S0140-6736(20)31604-4","article-title":"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1\/2, single-blind, randomised controlled trial","volume":"396","author":"Folegatti","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.blre.2023.101094_bb0220","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1001\/jamaoncol.2017.0184","article-title":"HER2-specific chimeric antigen receptor\u2013modified virus-specific T cells for progressive glioblastoma: a phase 1 dose-escalation trial","volume":"3","author":"Ahmed","year":"2017","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.blre.2023.101094_bb0225","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/s41392-021-00487-6","article-title":"Viral vector platforms within the gene therapy landscape","volume":"6","author":"Bulcha","year":"2021","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.blre.2023.101094_bb0230","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1006\/mthe.2000.0226","article-title":"Preclinical protocol for in vivo selection of hematopoietic stem cells corrected by gene therapy in Fanconi Anemia group C","volume":"3","author":"Noll","year":"2001","journal-title":"Mol Ther"},{"key":"10.1016\/j.blre.2023.101094_bb0235","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1182\/blood.V95.8.2499.008k35_2499_2504","article-title":"Development of lentiviral vectors for gene therapy for human diseases","volume":"95","author":"Buchschacher","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.blre.2023.101094_bb0240","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1006\/mthe.2001.0287","article-title":"Functional correction of Fanconi Anemia group C hematopoietic cells by the use of a novel lentiviral vector","volume":"3","author":"Yamada","year":"2001","journal-title":"Mol Ther"},{"key":"10.1016\/j.blre.2023.101094_bb0245","doi-asserted-by":"crossref","first-page":"2732","DOI":"10.1182\/blood-2002-04-1245","article-title":"Gene therapy of Fanconi anemia: preclinical efficacy using lentiviral vectors","volume":"100","author":"Galimi","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.blre.2023.101094_bb0250","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/S1525-0016(03)00223-5","article-title":"Phenotype correction of fanconi anemia group a hematopoietic stem cells using lentiviral vector","volume":"8","author":"Yamada","year":"2003","journal-title":"Mol Ther"},{"key":"10.1016\/j.blre.2023.101094_bb0255","doi-asserted-by":"crossref","first-page":"550","DOI":"10.2174\/1566523215666150929110903","article-title":"Lentiviral-mediated gene therapy in Fanconi Anemia-a mice reveals Long-term engraftment and continuous turnover of corrected HSCs","volume":"15","author":"Molina-Estevez","year":"2015","journal-title":"Curr Gene Ther"},{"key":"10.1016\/j.blre.2023.101094_bb0260","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.omtm.2021.06.001","article-title":"Improved collection of hematopoietic stem cells and progenitors from Fanconi anemia patients for gene therapy purposes","volume":"22","author":"Sevilla","year":"2021","journal-title":"Mol Ther - Methods Clin Dev"},{"key":"10.1016\/j.blre.2023.101094_bb0265","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1038\/s41591-019-0550-z","article-title":"Successful engraftment of gene-corrected hematopoietic stem cells in non-conditioned patients with Fanconi anemia","volume":"25","author":"R\u00edo","year":"2019","journal-title":"Nat Med"},{"key":"10.1016\/j.blre.2023.101094_bb0270","doi-asserted-by":"crossref","first-page":"835","DOI":"10.15252\/emmm.201303374","article-title":"Targeted gene therapy and cell reprogramming in Fanconi anemia","volume":"6","author":"Rio","year":"2014","journal-title":"EMBO Mol Med"},{"key":"10.1016\/j.blre.2023.101094_bb0275","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1126\/science.1231143","article-title":"Multiplex genome engineering using CRISPR\/Cas systems","volume":"339","author":"Cong","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.blre.2023.101094_bb0280","doi-asserted-by":"crossref","unstructured":"Liu M, Zhang W, Xin C, Yin J, Shang Y, Ai C, et al. Global detection of DNA repair outcomes induced by CRISPR\u2013Cas9. Nucleic Acids Res 2021;49:gkab686-. doi:https:\/\/doi.org\/10.1093\/nar\/gkab686.","DOI":"10.1101\/2021.02.15.431335"},{"key":"10.1016\/j.blre.2023.101094_bb0285","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1073\/pnas.0407796102","article-title":"Human Fanconi anemia monoubiquitination pathway promotes homologous DNA repair","volume":"102","author":"Nakanishi","year":"2005","journal-title":"Proc National Acad Sci"},{"key":"10.1016\/j.blre.2023.101094_bb0290","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1038\/s41588-018-0174-0","article-title":"CRISPR\u2013Cas9 genome editing in human cells occurs via the Fanconi anemia pathway","volume":"50","author":"Richardson","year":"2018","journal-title":"Nat Genet"},{"key":"10.1016\/j.blre.2023.101094_bb0295","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1089\/hum.2014.111","article-title":"Fanconi Anemia gene editing by the CRISPR\/Cas9 system","volume":"26","author":"Osborn","year":"2015","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.blre.2023.101094_bb0300","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1089\/scd.2016.0149","article-title":"CRISPR\/Cas9 targeted gene editing and cellular engineering in Fanconi Anemia","volume":"25","author":"Osborn","year":"2016","journal-title":"Stem Cells Dev"},{"key":"10.1016\/j.blre.2023.101094_bb0305","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.3390\/ijms18061269","article-title":"CRISPR\/Cas9-mediated correction of the FANCD1 gene in primary patient cells","volume":"18","author":"Kramarzova","year":"2017","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.blre.2023.101094_bb0310","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1038\/s41598-018-36506-w","article-title":"Effective CRISPR\/Cas9-mediated correction of a Fanconi anemia defect by error-prone end joining or templated repair","volume":"9","author":"van de Vrugt","year":"2019","journal-title":"Sci Rep-Uk"},{"key":"10.1016\/j.blre.2023.101094_bb0315","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.stem.2019.08.016","article-title":"NHEJ-mediated repair of CRISPR-Cas9-induced DNA breaks efficiently corrects mutations in HSPCs from patients with Fanconi Anemia","volume":"25","author":"Rom\u00e1n-Rodr\u00edguez","year":"2019","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.blre.2023.101094_bb0320","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1038\/mt.2016.172","article-title":"A self-restricted CRISPR system to reduce off-target effects","volume":"24","author":"Chen","year":"2016","journal-title":"Mol Ther"},{"key":"10.1016\/j.blre.2023.101094_bb0325","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1126\/science.aaq0180","article-title":"RNA editing with CRISPR-Cas13","volume":"358","author":"Cox","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.blre.2023.101094_bb0330","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1038\/nature17946","article-title":"Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage","volume":"533","author":"Komor","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.blre.2023.101094_bb0335","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1038\/nature24644","article-title":"Programmable base editing of a\u2022T to G\u2022C in genomic DNA without DNA cleavage","volume":"551","author":"Gaudelli","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.blre.2023.101094_bb0340","doi-asserted-by":"crossref","first-page":"8416","DOI":"10.3390\/ijms23158416","article-title":"Correction of Fanconi Anemia mutations using digital genome engineering","volume":"23","author":"Sipe","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.blre.2023.101094_bb0345","doi-asserted-by":"crossref","first-page":"6900","DOI":"10.1038\/s41467-022-34479-z","article-title":"Adenine base editing efficiently restores the function of Fanconi anemia hematopoietic stem and progenitor cells","volume":"13","author":"Siegner","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.blre.2023.101094_bb0350","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/s41586-019-1711-4","article-title":"Search-and-replace genome editing without double-strand breaks or donor DNA","volume":"576","author":"Anzalone","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.blre.2023.101094_bb0355","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/nature08129","article-title":"Disease-corrected haematopoietic progenitors from Fanconi anaemia induced pluripotent stem cells","volume":"460","author":"Raya","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.blre.2023.101094_bb0360","doi-asserted-by":"crossref","first-page":"5449","DOI":"10.1182\/blood-2012-02-408674","article-title":"Overcoming reprogramming resistance of Fanconi anemia cells","volume":"119","author":"M\u00fcller","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.blre.2023.101094_bb0365","doi-asserted-by":"crossref","first-page":"4330","DOI":"10.1038\/ncomms5330","article-title":"Modelling Fanconi anemia pathogenesis and therapeutics using integration-free patient-derived iPSCs","volume":"5","author":"Liu","year":"2014","journal-title":"Nat Commun"},{"key":"10.1016\/j.blre.2023.101094_bb0370","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1002\/stem.1308","article-title":"Brief report: human pluripotent stem cell models of Fanconi Anemia deficiency reveal an important role for Fanconi Anemia proteins in cellular reprogramming and survival of hematopoietic progenitors","volume":"31","author":"Yung","year":"2013","journal-title":"Stem Cells"},{"key":"10.1016\/j.blre.2023.101094_bb0375","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.stemcr.2015.12.001","article-title":"Overcoming pluripotent stem cell dependence on the repair of endogenous DNA damage","volume":"6","author":"Chlon","year":"2016","journal-title":"Stem Cell Rep"},{"key":"10.1016\/j.blre.2023.101094_bb0380","first-page":"4679","article-title":"An induced pluripotent stem cell model of Fanconi anemia reveals mechanisms of p53-driven progenitor cell differentiation","volume":"4","author":"Marion","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.blre.2023.101094_bb0385","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.jcyt.2022.11.014","article-title":"CRISPR\/Cas9-mediated gene editing. A promising strategy in hematological disorders","volume":"25","author":"Ugalde","year":"2023","journal-title":"Cytotherapy"},{"key":"10.1016\/j.blre.2023.101094_bb0390","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1097\/MOP.0000000000001196","article-title":"Inherited bone marrow failure syndromes: a review of current practices and potential future research directions","volume":"35","author":"Deng","year":"2023","journal-title":"Curr Opin Pediatr"},{"key":"10.1016\/j.blre.2023.101094_bb0395","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1146\/annurev-immunol-032713-120156","article-title":"Innate immune sensing and signaling of cytosolic nucleic acids","volume":"32","author":"Wu","year":"2014","journal-title":"Immunology"},{"key":"10.1016\/j.blre.2023.101094_bb0400","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1111\/imr.13022","article-title":"The molecular mechanism of RIG-I activation and signaling","volume":"304","author":"Thoresen","year":"2021","journal-title":"Immunol Rev"},{"key":"10.1016\/j.blre.2023.101094_bb0405","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.biomaterials.2017.11.034","article-title":"Emergence of synthetic mRNA: in vitro synthesis of mRNA and its applications in regenerative medicine","volume":"156","author":"Kwon","year":"2018","journal-title":"Biomaterials"},{"key":"10.1016\/j.blre.2023.101094_bb0410","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s12943-020-01263-w","article-title":"The role of m6A, m5C and \u03a8 RNA modifications in cancer: novel therapeutic opportunities","volume":"20","author":"Nombela","year":"2021","journal-title":"Mol Cancer"},{"key":"10.1016\/j.blre.2023.101094_bb0415","doi-asserted-by":"crossref","first-page":"e142","DOI":"10.1093\/nar\/gkr695","article-title":"Generating the optimal mRNA for therapy: HPLC purification eliminates immune activation and improves translation of nucleoside-modified, protein-encoding mRNA","volume":"39","author":"Karik\u00f3","year":"2011","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.blre.2023.101094_bb0420","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1016\/j.vaccine.2021.03.038","article-title":"mRNA vaccines manufacturing: challenges and bottlenecks","volume":"39","author":"Rosa","year":"2021","journal-title":"Vaccine"},{"key":"10.1016\/j.blre.2023.101094_bb0425","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1038\/s41578-021-00358-0","article-title":"Lipid nanoparticles for mRNA delivery","volume":"6","author":"Hou","year":"2021","journal-title":"Nat Rev Mater"},{"key":"10.1016\/j.blre.2023.101094_bb0430","doi-asserted-by":"crossref","first-page":"3828","DOI":"10.1039\/D1CS00617G","article-title":"Emerging mRNA technologies: delivery strategies and biomedical applications","volume":"51","author":"Xiao","year":"2022","journal-title":"Chem Soc Rev"},{"key":"10.1016\/j.blre.2023.101094_bb0435","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/s41576-021-00439-4","article-title":"Drug delivery systems for RNA therapeutics","volume":"23","author":"Paunovska","year":"2022","journal-title":"Nat Rev Genet"},{"key":"10.1016\/j.blre.2023.101094_bb0440","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/s41580-020-0251-y","article-title":"RNA delivery by extracellular vesicles in mammalian cells and its applications","volume":"21","author":"O\u2019Brien","year":"2020","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.blre.2023.101094_bb0445","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2109256118","article-title":"On the mechanism of tissue-specific mRNA delivery by selective organ targeting nanoparticles","volume":"118","author":"Dilliard","year":"2021","journal-title":"Proc National Acad Sci"},{"key":"10.1016\/j.blre.2023.101094_bb0450","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2116271119","article-title":"Lung-selective mRNA delivery of synthetic lipid nanoparticles for the treatment of pulmonary lymphangioleiomyomatosis","volume":"119","author":"Qiu","year":"2022","journal-title":"Proc National Acad Sci"},{"key":"10.1016\/j.blre.2023.101094_bb0455","first-page":"1","article-title":"Nanoparticle-mediated targeting of the fusion gene RUNX1\/ETO in t(8;21)-positive acute myeloid leukaemia","author":"Issa","year":"2023","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2023.101094_bb0460","doi-asserted-by":"crossref","DOI":"10.1021\/acs.nanolett.3c00304","article-title":"In vivo RNA delivery to hematopoietic stem and progenitor cells via targeted lipid nanoparticles","author":"Shi","year":"2023","journal-title":"Nano Lett"},{"key":"10.1016\/j.blre.2023.101094_bb0465","doi-asserted-by":"crossref","DOI":"10.3389\/fbioe.2021.628137","article-title":"The limitless future of RNA therapeutics","volume":"9","author":"Damase","year":"2021","journal-title":"Front Bioeng Biotechnol"},{"key":"10.1016\/j.blre.2023.101094_bb0470","doi-asserted-by":"crossref","first-page":"S86","DOI":"10.5045\/br.2022.2022056","article-title":"Genetics and genomics of bone marrow failure syndrome","volume":"57","author":"Kim","year":"2022","journal-title":"Blood Res"},{"key":"10.1016\/j.blre.2023.101094_bb0475","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3109\/08880018.2015.1129567","article-title":"Androgen therapy in Fanconi anemia: a retrospective analysis of 30 years in Germany","volume":"33","author":"Paustian","year":"2016","journal-title":"Pediatr Hematol Oncol"},{"key":"10.1016\/j.blre.2023.101094_bb0480","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1016\/j.bbmt.2016.03.007","article-title":"Long-term survival, organ function, and malignancy after hematopoietic stem cell transplantation for Fanconi Anemia","volume":"22","author":"Bonfim","year":"2016","journal-title":"Biol Blood Marrow Tr"},{"key":"10.1016\/j.blre.2023.101094_bb0485","doi-asserted-by":"crossref","first-page":"5943","DOI":"10.1007\/s00784-022-04554-2","article-title":"Tongue cancer following hematopoietic cell transplantation for Fanconi anemia","volume":"26","author":"Bartolomeo","year":"2022","journal-title":"Clin Oral Investig"},{"key":"10.1016\/j.blre.2023.101094_bb0490","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1038\/s41392-022-01007-w","article-title":"mRNA-based therapeutics: powerful and versatile tools to combat diseases","volume":"7","author":"Qin","year":"2022","journal-title":"Signal Transduct Target Ther"}],"container-title":["Blood Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X23000553?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X23000553?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T20:33:17Z","timestamp":1759437197000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0268960X23000553"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":98,"alternative-id":["S0268960X23000553"],"URL":"https:\/\/doi.org\/10.1016\/j.blre.2023.101094","relation":{},"ISSN":["0268-960X"],"issn-type":[{"value":"0268-960X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Beyond current treatment of Fanconi Anemia: What do advances in cell and gene-based approaches offer?","name":"articletitle","label":"Article Title"},{"value":"Blood Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.blre.2023.101094","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101094"}}